Bio-Techne Corporation

BOVESPA:T1CH34 Stock Report

Market Cap: R$41.4b

Bio-Techne Management

Management criteria checks 1/4

Bio-Techne's CEO is Kim Kelderman, appointed in Feb 2024, has a tenure of 1.25 years. total yearly compensation is $6.85M, comprised of 11.1% salary and 88.9% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth R$10.30M. The average tenure of the management team and the board of directors is 1.8 years and 8.3 years respectively.

Key information

Kim Kelderman

Chief executive officer

US$6.9m

Total compensation

CEO salary percentage11.08%
CEO tenure1.3yrs
CEO ownership0.02%
Management average tenure1.8yrs
Board average tenure8.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kim Kelderman's remuneration changed compared to Bio-Techne's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

US$132m

Dec 31 2024n/an/a

US$158m

Sep 30 2024n/an/a

US$151m

Jun 30 2024US$7mUS$760k

US$168m

Mar 31 2024n/an/a

US$203m

Dec 31 2023n/an/a

US$224m

Sep 30 2023n/an/a

US$247m

Jun 30 2023US$3mUS$590k

US$285m

Mar 31 2023n/an/a

US$271m

Dec 31 2022n/an/a

US$262m

Sep 30 2022n/an/a

US$292m

Jun 30 2022US$3mUS$562k

US$272m

Mar 31 2022n/an/a

US$225m

Dec 31 2021n/an/a

US$210m

Sep 30 2021n/an/a

US$177m

Jun 30 2021US$4mUS$530k

US$140m

Mar 31 2021n/an/a

US$184m

Dec 31 2020n/an/a

US$175m

Sep 30 2020n/an/a

US$248m

Jun 30 2020US$2mUS$500k

US$229m

Mar 31 2020n/an/a

US$187m

Dec 31 2019n/an/a

US$195m

Sep 30 2019n/an/a

US$93m

Jun 30 2019US$2mUS$452k

US$96m

Mar 31 2019n/an/a

US$121m

Dec 31 2018n/an/a

US$96m

Sep 30 2018n/an/a

US$128m

Jun 30 2018US$2mUS$73k

US$126m

Compensation vs Market: Kim's total compensation ($USD6.85M) is above average for companies of similar size in the BR market ($USD2.24M).

Compensation vs Earnings: Kim's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Kim Kelderman (57 yo)

1.3yrs
Tenure
US$6,852,495
Compensation

Mr. Kim Kelderman serves as Director of SLMP, LLC since November 2021. He serves as President of the Diagnostics and Genomics Segment at Bio-Techne. He served as Chief operating Officer at Bio-Techne Corpo...


Leadership Team

NamePositionTenureCompensationOwnership
Kim Kelderman
CEO, President & Director1.3yrsUS$6.85m0.025%
R$ 10.3m
James Hippel
Executive VP of Finance & CFO11.1yrsUS$5.20m0.068%
R$ 28.2m
Shane Bohnen
Senior VP2.2yrsUS$1.46m0.0020%
R$ 844.7k
William Geist
President of Protein Sciences Segment3.3yrsUS$3.65m0.0085%
R$ 3.5m
Matthew McManus
President of Diagnostics & Genomics1.3yrsUS$2.27m0.0019%
R$ 786.8k
Gary Latham
VP & CTO1.3yrsno datano data
David Clair
VP of Investor Relations & Corporate Developmentno datano datano data
Gerry Andros
Vice President of Sales and Marketingno datano datano data
Martin Wirtz
Senior Vice President of Strategy & Corporate Development1.3yrsno datano data
Cheryl Bethune
Senior VP & Chief Human Resources Officerless than a yearno datano data
Luca Cicchetti
Managing Director8.8yrsno datano data
Steven Crouse
Senior Vice President of Analytical Solutions Division2.3yrsno datano data
1.8yrs
Average Tenure
54yo
Average Age

Experienced Management: T1CH34's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Kim Kelderman
CEO, President & Director2.3yrsUS$6.85m0.025%
R$ 10.3m
Robert Baumgartner
Independent Chairman of the Board22.3yrsUS$410.46k0.029%
R$ 11.9m
John Higgins
Independent Director16yrsUS$300.46k0.038%
R$ 15.9m
Joseph Keegan
Independent Director8.3yrsUS$275.46k0.0088%
R$ 3.6m
Roeland Nusse
Independent Director15yrsUS$290.46k0.028%
R$ 11.8m
Julie Bushman
Independent Director4.8yrsUS$291.50k0.0046%
R$ 1.9m
John Denu
Member of Scientific Advisory Boardno datano datano data
Sachdev Sidhu
Member of Scientific Advisory Boardno datano datano data
Alpna Seth
Independent Director8.3yrsUS$275.46k0.0088%
R$ 3.6m
David Artis
Member of Scientific Advisory Boardno datano datano data
Judith Klimovsky
Independent Director1.1yrsUS$113.73k0.0014%
R$ 567.3k
S. J. Vessey
Independent Director5.9yrsUS$275.46k0.0060%
R$ 2.5m
8.3yrs
Average Tenure
63yo
Average Age

Experienced Board: T1CH34's board of directors are considered experienced (8.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/25 23:55
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Techne Corporation is covered by 30 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
James Francis MainwaringAtlantic Equities LLP
Catherine Ramsey SchulteBaird